

## Citations

1. Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. *J Clin Psychopharmacol* 2000;20:84-89.
2. Pittler MH, Ernst E. Kava extract for treating anxiety. *Cochrane Database Syst Rev* 2003;CD003383.
3. Ernst E. Herbal remedies for anxiety: a systematic review of controlled clinical trials. *Phytomedicine* 2006;13:205-208.
4. BHMA. *Piper methysticum*. British Herbal Pharmacopoeia. Bournemouth, UK: British Herbal Medicine Association; 1983:215.
5. Kava kava. In: Blumenthal M, Busse W, Goldberg A, et al, eds. *The Complete German Commission E Monographs*. Austin, Texas: American Botanical Council: Integrative Medicine Communications; 1998:156-157.
6. WHO. *Rhizoma Piperis Methystici*. WHO Monographs on Selected Medicinal Plants. 2 vol. Geneva: World Health Organization; 2002:231-245.
7. ESCOP. *Piperis Methystici Rhizoma*. ESCOP Monographs: the Scientific Foundation for Herbal Medicinal Products. 2nd ed. Exeter, UK: European Scientific Cooperative on Phytotherapy and Thieme; 2003:365-382.
8. Singh Y. *Kava from Ethnology to Pharmacology*. Boca Raton, Fla: CRC Press; 2004.
9. Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. *Ann Intern Med* 2001;135:68-69.
10. Campo JV, McNabb J, Perel JM et al. Kava-induced fulminant hepatic failure. *J Am Acad Child Adolesc Psychiatry* 2002;41:631-632.
11. McGhee H. From the Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products —United States, Germany, and Switzerland, 1999-2002. *JAMA* 2003;289:36-37.
12. Gow PJ, Connelly NJ, Hill RL et al. Fatal fulminant hepatic failure induced by a natural therapy containing kava. *Med J Aust* 2003;178:442-443.
13. Brauer RB, Stangl M, Stewart JR et al. Acute liver failure after administration of herbal tranquilizer kava-kava (*Piper methysticum*). *J Clin Psychiatry* 2003;64:216-218.
14. Stickel F, Baumuller H-M, Seitz K et al. Hepatitis induced by kava (*Piper methysticum rhizoma*). *J Hepatol* 2003;39:62-67.
15. Strahl S, Ehret V, Dahm HH, Maier KP. [Necrotizing hepatitis after taking herbal remedies]. *Dtsch Med Wochenschr* 1998;123:1410-1414.
16. Schmidt M. Is kava really hepatotoxic? Accessed February 2005 vol; 2003:<http://www.uni-muenster.de/Chemie.pb/Kava/kavaframe.html>.
17. Schmidt M, Morgan M, Bone K et al. Kava: a risk-benefit assessment. In: Mills S, Bone K, eds. *The Essential Guide to Herbal Safety*. St Louis: Churchill Livingstone; 2005:155-201.
18. Cerna D. *The Pharmacology of the Newer Materia Medica*. Detroit: George Davis; 1892.
19. Ellingwood F, Lloyd J. *The American Materia Medica: Therapeutics and Pharmacognosy*. Eclectic Medical Publications, Portland, Ore; 1983 ed. Cincinnati; 1919.
20. Weiss R. *Herbal Medicine*. Meuss A, Translator. 6th ed. Beaconsfield, UK: Beaconsfield Publishers Ltd; 1988.
21. Hänsel R. Characterization and physiological activity of some kava constituents. *Pac Sci* 1968;22:293-313.
22. Lebot V, Johnston E, Zheng Q et al. Morphological, phytochemical and genetic variation in Hawaiian cultivars of 'awa (*Piper methysticum*, Piperaceae). *Econ Bot* 1999;53:407-418.
23. Cheng D, Lidgard RO, Duffield PH et al. Identification by methane chemical ionization gas chromatography/mass spectrometry of the products obtained by steam distillation and aqueous acid extraction of commercial *Piper methysticum*. *Biomed Environ Mass Spectrom* 1988;17:371-376.
24. Rasmussen P. Phytotherapy for the treatment of drug withdrawal. *Eur J Herbal Med* 1997;3:11-22.
25. Waller D. Report on kava and liver damage. American Herbal Products Association; Silver Spring, Md. University of Illinois at Chicago, Department of Pharmaceutics and Pharmacodynamics; 2002.
26. Anke J, Ramzan I. Kava hepatotoxicity: are we any closer to the truth? *Planta Med* 2004;70:193-196.
27. Singh N, Singh S, Singh Y. Kava: clinical studies and therapeutic implications. In: Singh Y, ed. *Kava from Ethnology to Pharmacology*. Boca Raton, Fla: CRC Press; 2004:140-164.
28. Cloutre DL. Kava kava: examining new reports of toxicity. *Toxicol Lett* 2004;150:85-96.
29. Kava Kava: Declaration of the German Commission E [in German]. *Z Phytotherapie* 2002;4:158.
30. Bauer R, Kopp B, Nahrstedt A. Relevant hepatotoxic effects of kava still need to be proven. *Planta Med* 2003;69:971-972.
31. Dragull K, Yoshida WY, Tang C-S. Piperidine alkaloids from *Piper methysticum*. *Phytochemistry* 2003;63:193-198.
32. Whitton PA, Lau A, Salisbury A et al. Kava lactones and the kava-kava controversy. *Phytochemistry* 2003;64:673-679.

## Citations and Reference Literature: Kava

33. Schmidt M. Are kavalactones the hepatotoxic principle of kava extracts? The pitfalls of the glutathione theory. *J Altern Complement Med* 2003;9:183-187; author reply 187-188.
34. Li AP. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. *Chem Biol Interact* 2002;142:7-23.
35. Mathews JM, Etheridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. *Drug Metab Dispos* 2002;30:1153-1157.
36. Unger M, Holzgrabe U, Jacobsen W et al. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of *Piper methysticum* (kava-kava). *Planta Med* 2002;68:1055-1058.
37. Zou L, Henderson GL, Harkey MR et al. Effects of kava (kava-kava, 'awa, yaqona, *Piper methysticum*) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. *Phytomedicine* 2004;11:285-294.
38. Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. *Life Sci* 2002;71:1579-1589.
39. Cote CS, Kor C, Cohen J, Auclair K. Composition and biological activity of traditional and commercial kava extracts. *Biochem Biophys Res Commun* 2004;322:147-152.
40. Russmann S, Barguil Y, Wenk M et al. Traditional aqueous kava extracts inhibit CYP4501A2 in humans. *Clin Pharmacol Ther* 2004;75:P83.
41. Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. *Drug Metab Dispos* 2003;31:533-539.
42. Gurley BJ, Gardner SF, Hubbard MA et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. *Clin Pharmacol Ther* 2005;77:415-426.
43. Zou L, Harkey MR, Henderson GL. Synthesis, in vitro reactivity, and identification of 6-phenyl-3-hexen-2-one in human urine after kava-kava (*Piper methysticum*) ingestion. *Planta Med* 2005;71:142-146.
44. Tarbah F, Mahler H, Kardel B et al. Kinetics of kavain and its metabolites after oral application. *J Chromatogr B Analyt Technol Biomed Life Sci* 2003;789:115-130.
45. Russmann S, Lauterburg BH, Barguil Y et al. Traditional aqueous kava extracts inhibit cytochrome P450 1A2 in humans: protective effect against environmental carcinogens? *Clin Pharmacol Ther* 2005;77:453-454.
46. Steiner GG. The correlation between cancer incidence and kava consumption. *Hawaii Med J* 2000;59:420-422.
47. Folmer F, Blasius R, Morceau F et al. Inhibition of TNF $\alpha$ -induced activation of nuclear factor  $\kappa$ B by kava (*Piper methysticum*) derivatives. *Biochem Pharmacol* 2006;71:1206-1218.
48. Singh YN. Potential for interaction of kava and St. John's wort with drugs. *J Ethnopharmacol* 2005;100:108-113.
49. Anke J, Ramzan I. Pharmacokinetic and pharmacodynamic drug interactions with kava (*Piper methysticum* Forst. f.). *J Ethnopharmacol* 2004;93:153-160.
50. Wanwimolruk S, Bhawan S, Coville PF, Chalcroft SC. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. *Eur J Clin Pharmacol* 1998;54:431-435.
51. Klohs MW, Keller F, Williams RE et al. A chemical and pharmacological investigation of *Piper methysticum* Forst. *J Med Pharm Chem* 1959;1:95-103.
52. Meyer HJ. [Pharmacology of the active principles of kavaroot (*Piper methysticum* Forst.)]. *Arch Int Pharmacodyn Ther* 1962;138:505-536.
53. Herberg K. Safety-related performance after intake of kava-extract, bromazepam, and their combination. *Z Allgemeinmed* 1996;72:973-977.
54. Jamieson DD, Duffield PH. The antinociceptive actions of kava components in mice. *Clin Exp Pharmacol Physiol* 1990;17:495-507.
55. Davies LP, Drew CA, Duffield P et al. Kava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain. *Pharmacol Toxicol* 1992;71:120-126.
56. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from *Piper methysticum* as modulator of the GABA binding site in different regions of rat brain. *Psychopharmacology (Berl)* 1994;116:469-474.
57. Holm E, Staedt U, Heep J et al. [The action profile of d,l-kavain: cerebral sites and sleep-wakefulness-rhythm in animals]. *Arzneimittelforschung* 1991;41:673-683.
58. Singh Y. Pharmacology and toxicology of kava and kavalactones. In: Singh Y, ed. *Kava from Ethnology to Pharmacology*. Boca Raton, Fla: CRC Press; 2004:104-139.
59. Noyes R Jr, DuPont RL Jr, Pecknold JC et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety. *Arch Gen Psychiatry* 1988;45:423-428.
60. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. *Ann Intern Med* 1996;125:940-941.

## Citations and Reference Literature: Kava

61. Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. *Br J Clin Pharmacol* 2001;52:587-595.
62. Capasso A, Sorrentino L. Pharmacological studies on the sedative and hypnotic effect of kava kava and Passiflora extracts combination. *Phytomedicine* 2005;12:39-45.
63. Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. *Prog Neuropsychopharmacol Biol Psychiatry* 1998;22:1105-1120.
64. Noldner M, Chatterjee SS. Inhibition of haloperidol-induced catalepsy in rats by root extracts from *Piper methysticum* F. *Phytomedicine* 1999;6:285-286.
65. Schelosky L, Raffauf C, Jendroska K, Poewe W. Kava and dopamine antagonism. *J Neurol Neurosurg Psychiatry* 1995;58:639-640.
66. Meseguer E, Taboada R, Sanchez V et al. Life-threatening parkinsonism induced by kava-kava. *Mov Disord* 2002;17:195-196.
67. Pepping J. Kava: *Piper methysticum*. *Am J Health Syst Pharm* 1999;56:957-958, 960.
68. Jamieson DD, Duffield PH. Positive interaction of ethanol and kava resin in mice. *Clin Exp Pharmacol Physiol* 1990;17:509-514.
69. Herberg KW. [Effect of Kava-Special Extract WS 1490 combined with ethyl alcohol on safety-relevant performance parameters]. *Blutalkohol* 1993;30:96-105.
70. Foo H, Lemon J. Acute effects of kava, alone or in combination with alcohol on subjective measures of impairment and intoxication and on cognitive performance. *Drug Alcohol Rev* 1997;16:147-155.
71. Anke J, Fu S, Ramzan I. Kavalactones fail to inhibit alcohol dehydrogenase in vitro. *Phytomedicine* 2006;13:192-195.
72. Mathews JD, Riley MD, Fejo L et al. Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community. *Med J Aust* 1988;148:548-555.
73. Kretzschmar R, Meyer HJ, Teschendorf HJ. Strychnine antagonistic potency of pyrone compounds of the kavaroot (*Piper methysticum* Forst.). *Experientia* 1970;26:283-284.
74. Kretzschmar R, Meyer HJ. [Comparative studies on the anticonvulsant activity of the pyrone compounds of *Piper methysticum* Forst]. *Arch Int Pharmacodyn Ther* 1969;177:261-267.
75. Jamieson DD, Duffield PH, Cheng D, Duffield AM. Comparison of the central nervous system activity of the aqueous and lipid extract of kava (*Piper methysticum*). *Arch Int Pharmacodyn Ther* 1989;301:66-80.
76. Frey R. [Demonstration of the central effects of d,l-kavain with EEG brain mapping]. *Fortschr Med* 1991;109:505-508.
77. Spinella M. Herbal medicines and epilepsy: the potential for benefit and adverse effects. *Epilepsy Behav* 2001;2:524-532.
78. Donadio V, Bonsi P, Zele I et al. Myoglobinuria after ingestion of extracts of guarana, *Ginkgo biloba* and kava. *Neurol Sci* 2000;21:124.
79. Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from *Piper methysticum* Forster (kava-kava). *Pharmacopsychiatry* 1998;31:187-192.
80. Navarro JF, Gallego E, Aviles J. Recurrent severe acute hepatitis and omeprazole. *Ann Intern Med* 1997;127:1135-1136.
81. Koury SI, Stone CK, La Charite DD. Omeprazole and the development of acute hepatitis. *Eur J Emerg Med* 1998;5:467-469.
82. Romero-Gomez M, Otero MA, Suarez-Garcia E et al. Acute hepatitis related to omeprazole. *Am J Gastroenterol* 1999;94:1119-1120.
83. Christe C, Stoller R, Vogt N. Omeprazole-induced hepatotoxicity? A case report. *Pharmacoepidemiol Drug Saf* 1998;7 Suppl 1:S41-44.
84. Gleitz J, Beile A, Wilkens P et al. Antithrombotic action of the kava pyrone (+)-kavain prepared from *Piper methysticum* on human platelets. *Planta Med* 1997;63:27-30.
85. Mills S, Bone K. *The Essential Guide to Herbal Safety*. St Louis: Churchill Livingstone; 2005.